#Japan #medical technology #Hino #Biolismedical #Sakae

Biolismedical: A New Chapter in Medical Technology

Tokyo Trading Medisys has embarked on an exciting rebranding journey, officially adopting the new title, Biolismedical Co., Ltd. as of September 1, 2025. This strategic move reflects a significant shift in the company’s mission as it continues to expand its reach in the medical technology sector. With this transformation, Biolismedical aims to enhance its product development and strengthen its global sales presence.

Founded on July 1, 1999, Biolismedical specializes in the development, manufacture, and sale of biochemical analyzers, with their flagship product being the Biolis Series, an advanced tabletop biochemical automatic analyzer. The rebranding decision stems from the desire to better align the company name with its core products, thereby resonating more effectively with its target market.

The Sakae Group, which welcomed Tokyo Trading Medisys into the fold on February 28, 2025, is spearheaded by CEO Hirokazu Matsumoto. This acquisition heralds a new era for both companies, aiming to consolidate their technological expertise in tabletop chemical analysis devices. The synergy created between the two entities is expected to facilitate innovative product development and pave the way for enhanced international market penetration.

Biolismedical intends to leverage Sakae's extensive global network, significantly boosting the overseas sales of its products. With this rebranding, the company is not only setting its sights on expanding its business but also on revitalizing and exploring new markets abroad. The ultimate goal is to harness the strengths of both organizations to foster growth and innovation.

Key Business and Operations

Biolismedical's headquarters is located in Hino City, Tokyo, at 1-14-21 Higashitoyoda, while it has sales offices in Sapporo, Sendai, Tokyo, Nagoya, Osaka, and Fukuoka. The company currently employs 64 staff members as of June 1, 2025 and serves a diverse clientele that includes hospitals, clinics, universities, research institutions, companies, and testing centers.

The main activities of Biolismedical include:
1. Development, manufacturing, and sales of biochemical analyzers.
2. Sales of clinical testing equipment and related products.
3. Development and sales of clinical testing systems.

To celebrate the launch of Biolismedical, the company will participate in the JACLASEXPO 2025, a comprehensive exhibition for clinical testing equipment, reagents, and systems, taking place from October 3 to 5, 2025 at Pacifico Yokohama. This marks Biolismedical's first exhibition appearance under its new name, showcasing its commitment to innovation in clinical diagnostics.

About Sakae Corporation

Sakae Corporation, which plays a pivotal role in this transition, was established in July 1952 and is headquartered in Minato, Tokyo. With a capital of 93 million yen, Sakae specializes in clinical medical devices, including diabetes testing instruments and in vitro diagnostic test reagents. The company also engages in OEM contracts for clinical testing devices and manufactures both consumer and industrial heating equipment. As of April 1, 2025, the workforce comprises 150 employees.

• - Sakae’s website: Sakae Corporation
• - Biolismedical’s website (launched on September 1, 2025): Biolismedical

The rebranding of Biolismedical underlines a significant development in the medical device industry, indicating a forward-thinking approach and a dedication to advancing healthcare technology globally. As the medical landscape evolves, Biolismedical is poised to be at the forefront, bringing innovative solutions to healthcare professionals and patients alike.